Those who applied for
Congratulations to everyone who applied for the free trial. ^^
※ For those who missed the “COVID-19 treatment” opportunity, don’t worry. We are launching another big opportunity.
※ Finally starting. Korea Union Pharmaceutical (080720) follow-up stock hits the daily limit on Monday. ※
When creating artificial organs that can be transplanted into humans, ‘vascularization’ is necessary. Artificial organs without blood vessels are highly likely to cause complications such as thrombosis inside blood vessels after transplantation as the recipient’s blood vessels connect!!
Domestic researchers have succeeded in creating artificial organs including blood vessels. According to the bio industry, Professor Kyung-Sun Kang’s research team at Seoul National University reconstructed artificial organs including blood vessels that allow blood flow based on a biological scaffold, and published their research results in the international journal ‘Biomaterials’!!
“I applied and invested a very small amount for 3 days, but I was surprised to see daily limit profits every day. It felt like a dream or reality. I kept receiving it and it was a daily limit march. It’s really amazing. Now I pay the membership fee and receive VIP service, and the membership fee feels so cheap compared to how much I earn daily. I can only say thank you. Thank you.”
(VIP Self-employed Member Jin Young-hoon, 42 years old)
Think of this as the last chance. If you miss this opportunity, you have to give up.
Exactly on “October 12” it will explode! Don’t miss out and regret it, buy at least 100,000 KRW worth!
▶▶ Only 10 people will be given. “Monday daily limit”! ▶ Receive now ◀
※ First-come, first-served 10 people closed! Both early and late rounds are over. The hero of the last injury time winning goal ※
[Today’s stocks of interest]
#KoreaUnionPharmaceutical #SCMLifeScience #YoungjinPharmaceutical #KwangdongPharmaceutical #TheragenEtex
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

